Navigation Links
Celladon Corporation To Present at BioCentury Future Leaders in the Biotech Industry Conference
Date:3/29/2013

sprinolactone/diuretics, and biventricular pacing devices. No treatment substitution decision is required by the treating physician. A recent Phase 2 clinical trial demonstrated sustained improvement at one year in cardiac function parameters and quality of life. A 200 patient Phase 2b study of MYDICAR was initiated in August 2012.

About the CUPID Phase 2b Trial

The CUPID Phase 2b trial was initiated in August 2012 and will enroll approximately 200 patients in up to 50 sites worldwide.  Patients will first be prescreened for the presence of AAV neutralizing antibodies. Those patients with a negative titer will undergo further screening tests and procedures to determine eligibility prior to randomization and enrollment into the study. All patients will be randomized in parallel to MYDICAR or placebo in a ratio of 1:1 (1 x 1013 DRP MYDICAR to placebo).

The primary objective is to determine the efficacy of MYDICAR in patients with ischemic or dilated cardiomyopathy and NYHA class III/IV symptoms of HF by reducing the frequency and/or delaying HF-related hospitalizations compared to placebo-treated patients.

The primary efficacy endpoint is time-to-recurrent HF-related hospitalizations in the presence of terminal events (all-cause death, heart transplant, LVAD implantation). The secondary efficacy endpoint is the time-to-terminal event (all-cause death, heart transplant, LVAD implantation). Exploratory endpoints include change from baseline in NYHA class, 6 minute walk test distance, and quality of life (KCCQ) score.

Secondary objectives will include assessment of the safety of MYDICAR by determining the incidence and severity of adverse events and changes in laboratory parameters. Safety evaluations include the incidence and severity of all adverse events (including procedure-related), summaries of concomitant medications, vital signs, physical exams, implantable cardioverter defibrillator (ICD) interrogations and la
'/>"/>

SOURCE Celladon Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Celladon Corporation Named a 2012 Fierce 15 Company by FierceBiotech
2. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
3. Kensey Nash Corporation Announces Achievement of $6 Million Milestone From Spectranetics Corporation
4. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
5. Neogen Corporation Announces 2nd Quarter Results Conference Call
6. Luminex Corporation to Present at JP Morgan Healthcare Conference
7. Luminex Corporation Fourth Quarter and Full Year 2011 Earnings Release Scheduled for February 6, 2012
8. Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
9. JBT Corporation and Swisslog Enter Into Partnership for Automated Guided Vehicles
10. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
11. Verenium Corporation to Announce Fourth Quarter and Year-End 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... May 21, 2015 Tunnell Consulting, ... the firm as senior statistician and Principal, a position ... experience in the management and analysis of complex and ... chemical industries. , “We’re delighted to have Julia join ... data analytics,” said Dr. Philippe Cini, Group Vice President ...
(Date:5/20/2015)... MECHANICSBURG, Pa. , May 20, 2015 /PRNewswire/ ... announced that the Federal Trade Commission granted early ... (HSR) Antitrust Improvements Act of 1976, as amended, ... by MJ Acquisition Corporation, a joint venture that ... XII, L.P. As previously announced, MJ ...
(Date:5/20/2015)... -- Haemonetics Corporation (NYSE: HAE ) announced today that ... at The Jefferies 2015 Global Healthcare Conference in ... , 2015 at 8:30am Eastern time.  ... webcast at: http://wsw.com/webcast/jeff88/hae ... a global healthcare company dedicated to providing innovative blood ...
(Date:5/20/2015)... (PRWEB) May 20, 2015 Optivia ... assay services for Drug-Drug Interactions (DDI), Metabolism and ... a world leader in assessing impact of drugs ... Pharmacology supported by biosimulation, announced today that they ... allows both companies to expand their product and ...
Breaking Biology Technology:Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2Optivia Biotechnology Inc. and Rhenovia Pharma Sign Partnership Agreement 2Optivia Biotechnology Inc. and Rhenovia Pharma Sign Partnership Agreement 3
... exploration to remote regions, to include distant planetary bodies, ... repetition, even the simplest tasks. With this in mind, ... into a novel approach that could some day aid ... power-intense options often used today. Integrating the NRL ...
...  S.E.D. Medical Laboratories will soon become part of Quest ... leader in diagnostic testing, information and services, through a ... Quest Diagnostics.  According to the agreement, Quest Diagnostics will ... in-patient labs for the four Lovelace hospitals, as well ...
... NeoStem Shareholders, We would like to take a ... for NeoStem (NYSE Amex: NBS ) – and to ... the company forward in 2012 and beyond. , We have ... LLC ("Amorcyte"). , We believe our therapeutic product development team ...
Cached Biology Technology:Navy researchers investigate small-scale autonomous planetary explorers 2S.E.D. Labs to be Acquired by Quest Diagnostics 2S.E.D. Labs to be Acquired by Quest Diagnostics 3NeoStem's CEO Letter to Shareholders 2NeoStem's CEO Letter to Shareholders 3NeoStem's CEO Letter to Shareholders 4
(Date:5/22/2015)... 2015 According to a new ... 3D, Thermal, Emotion, Forensic), by Software (Middleware, Databases), by Hardware ... Consumer and Home) - Global Forecast to 2020", published ... Billion in 2015 to $6.19 Billion by 2020, at ... market data Tables and   43 Figures spread through ...
(Date:5/21/2015)... The Sync Project™ , a global ... today announced a collaborative partnership with Berklee,s Institute ... on collaboration on original research, joint course development and ... collaboration, The Sync Project and BerkleeICE are exploring the ... the 2015-2016 academic year.  The course ...
(Date:5/20/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... 3D-ID LLC, a company engaged in biometric identification is ... technology portion of the recently awarded TIES (Technical Information ... the Army. 3D-ID LLC has a suite ... enforcement and security agencies. Gino Pereira ...
Breaking Biology News(10 mins):Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
... that living a stressful lifestyle can take its toll, making us ... around the office. The same appears to be true of ... published Nov. 10 in the journal Nature , dopamine-releasing neurons ... a lifestyle that requires lots of energy, creating stress that could ...
... a foreign object such as a catheter enters the body, ... a slick coating a biofilm that is highly ... be defeated by a basic approach of conventional means. Instead ... the key players in the network and how they operate. ...
... , The researchers characterize their new technique as a neat ... microscopy, but it,s more like the difference between finding the ... until you fall over it, or using a flashlight. In ... the National Institute of Standards and Technology (NIST) and the ...
Cached Biology News:Stress takes its toll in Parkinson's disease 2Research provides new leads in the case against drug-resistant biofilms 2AFM positioning: Shining light on a needle in a haystack 2
Ultra-sensitive, non-radioactive detection of Protein G. Measure Protein G levels quickly and easily....
TRIS-EDTA based buffer prepared from RNase-free water suitable for storage and dilution of siRNA, pH 8, store at 4 C ...
Request Info...
Ultra-sensitive, non-radioactive detection of rat Osteopontin...
Biology Products: